吉西他滨的耐药性及其结构修饰研究进展
Research Progress in Drug Resistance and Structural Modification of Gemcitabine
DOI: 10.12677/PI.2023.122010, PDF,   
作者: 万 悦, 阮奔放：浙江工业大学药学院，浙江 杭州
关键词: 吉西他滨；耐药性；结构修饰；Gemcitabine； Drug Resistance； Structural Modification
摘要: 吉西他滨是FDA批准为一种治疗多种癌症的化疗药物，被广泛应用于治疗各种实体瘤。虽然吉西他滨在临床上成功应用，但其较短的血浆半衰期，向细胞扩散较差，以及不良毒性降低其化疗潜力。吉西他滨的临床表现受到其不满意的药代动力学参数和易失活的严重限制，主要是由于吉西他滨快速脱氨作用，以及活化吉西他滨的脱氧胞苷激酶(DCK)缺乏和核苷转运蛋白的改变等。因此，设计合成吉西他滨的前体药物以提高吉西他滨的治疗效果至关重要。
Abstract: Gemcitabine is a chemotherapy drug approved by FDA for the treatment of multiple cancers, and is widely used for the treatment of various solid tumors. Although gemcitabine has been successfully used in clinical practice, its short plasma half-life, poor cell diffusion and adverse toxicity reduce its chemotherapy potential. The clinical performance of gemcitabine is severely limited by its unsatis-fied pharmacokinetic parameters and easy inactivation, mainly due to the rapid deamination of gemcitabine, the lack of deoxycytidine kinase (DCK) activated by gemcitabine and the change of nucleoside transporter. Therefore, it is very important to design and synthesize the precursor drugs of gemcitabine to improve the therapeutic effect of gemcitabine.
文章引用：万悦, 阮奔放. 吉西他滨的耐药性及其结构修饰研究进展[J]. 药物资讯, 2023, 12(2): 81-86. https://doi.org/10.12677/PI.2023.122010

参考文献

[1] Hui, Y.F. and Reitz, J. (2012) Gemcitabine: A Critical Nucleoside for Cancer Therapy. Current Medicinal Chemistry, 19, 1076-1087. [Google Scholar] [CrossRef] [PubMed]
[2] Gesto, D.S., Cerqueira, N., Fernandes, P.A. and Ramos, M.J. (2012) Gemcitabine: A Critical Nucleoside for Cancer Therapy. Current Medicinal Chemistry, 19, 1076-1087. [Google Scholar] [CrossRef] [PubMed]
[3] Hertel, L.W., Kroin, J.S., Misner, J.W. and Tustin, J.M. (1988) Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2’-difluoro-D-ribofuranosyl Nucleosides. The Journal of Organic Chemistry, 53, 2406-2409. [Google Scholar] [CrossRef] 
[4] Hertel, L.W., Boder, G.B., Kroin, J.S., et al. (1990) Evaluation of the Antitumor Activity of Gemcitabine (2’,2’-difluoro-2’-deoxycytidine). Cancer Research, 50, 4417-4422.
[5] Moysan, E., Bastiat, G. and Benoit, J.-P. (2013) Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics, 10, 430-444. [Google Scholar] [CrossRef] [PubMed]
[6] Abbruzzese, J.L., Grunewald, R., Weeks, E.A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W. and Raber, M.N. (1991) A Phase I Clinical, Plasma, and Cellular Pharmacology Study of Gemcitabine. Journal of Clinical Oncology, 9, 491-498. [Google Scholar] [CrossRef] 
[7] Hu, G., Li, F., Ouyang, K., et al. (2011) Intrinsic Gemcitabine Re-sistance in a Novel Pancreatic Cancer Cell Line. International Journal of Oncology, 40, 798-806.
[8] MMoysaoysan, E., Bastiat, G. and Benoit, J.-P. (2013) Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics, 10, 430-444. [Google Scholar] [CrossRef] [PubMed]
[9] Dubey, R.D., Saneja, A., Gupta, P.K. and Gupta, P.N. (2016) Recent Advances in Drug Delivery Strategies for Improved Ther-apeutic Efficacy of Gemcitabine. European Journal of Pharmaceutical Sciences, 93, 147-162. [Google Scholar] [CrossRef] [PubMed]
[10] Dasanu, C.A. (2008) Gemcitabine: Vascular Toxicity and Pro-thrombotic Potential. Expert Opinion on Drug Safety, 7, 703-716. [Google Scholar] [CrossRef] [PubMed]
[11] Cavaliere, A., Probst, K.C., Westwell, A.D. and Slusarczyk, M. (2017) Fluorinated Nucleosides as an Important Class of Anticancer and Antiviral Agents. Future Medicinal Chemistry, 9, 1809-1833. [Google Scholar] [CrossRef] [PubMed]
[12] Reddy, L.H. and Couvreur, P. (2009) Squalene: A Natural Triterpene for Use in Disease Management and Therapy. Advanced Drug Delivery Reviews, 61, 1412-1426. [Google Scholar] [CrossRef] [PubMed]
[13] Sobot, D., Mura, S., Yesylevskyy, S.O., et al. (2017) Conjugation of Squalene to Gemcitabine as Unique Approach Exploiting Endogenous Lipoproteins for Drug Delivery. Nature Com-munications, 8, Article No. 15678. [Google Scholar] [CrossRef] [PubMed]
[14] Réjiba, S., Reddy, L.H., Bigand, C., et al. (2011) Squalenoyl Gemcita-bine Nanomedicine Overcomes the Low Efficacy of Gemcitabine Therapy in Pancreatic Cancer. Nanomedicine: Nano-technology, Biology and Medicine, 7, 841-849. [Google Scholar] [CrossRef] [PubMed]
[15] Harivardhan Reddy, L., Ferreira, H., Dubernet, C., et al. (2008) Oral Absorption and Tissue Distribution of a New Squalenoyl Anticancer Nanomedicine. Journal of Nanoparticle Re-search, 10, 887-891. [Google Scholar] [CrossRef] 
[16] Suk, J.S., Xu, Q., Kim, N., Hanes, J. and Ensign, L.M. (2016) PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery. Advanced Drug Delivery Reviews, 99, 28-51. [Google Scholar] [CrossRef] [PubMed]
[17] Zhao, X., Si, J., Huang, D., Li, K., Xin, Y. and Sui, M. (2020) Application of Star Poly(ethylene glycol) Derivatives in Drug Delivery and Controlled Release. Journal of Controlled Release, 323, 565-577. [Google Scholar] [CrossRef] [PubMed]
[18] Mero, A., Clementi, C., Veronese, F.M. and Pasut, G. (2011) Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods. Bioconjugation Pro-tocols, 751, 95-129. [Google Scholar] [CrossRef] [PubMed]
[19] Adema, A.D., Bijnsdorp, I.V., Sandvold, M.L., Verheul, H.M. and Peters, G.J. (2009) Innovations and Opportunities to Improve Conventional (Deoxy)nucleoside and Fluoropyrimi-dine Analogs in Cancer. Current Medicinal Chemistry, 16, 4632-4643. [Google Scholar] [CrossRef] [PubMed]
[20] Bergman, A.M., Adema, A.D., Balzarini, J., et al. (2011) Anti-proliferative Activity, Mechanism of Action and Oral Antitumor Activity of CP-4126, a Fatty Acid Derivative of Gem-citabine, in in Vitro and in Vivo Tumor Models. Investigational New Drugs, 29, 456-466. [Google Scholar] [CrossRef] [PubMed]
[21] Pradere, U., Garnier-Amblard, E.C., Coats, S.J., Amblard, F. and Schinazi, R.F. (2014) Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs. Chemical Reviews, 114, 9154-9218. [Google Scholar] [CrossRef] [PubMed]
[22] Blagden, S.P., Rizzuto, I., Suppiah, P., et al. (2018) An-ti-Tumour Activity of a First-in-Class Agent NUC-1031 in Patients with Advanced Cancer: Results of a Phase I Study. British Journal of Cancer, 119, 815-822. [Google Scholar] [CrossRef] [PubMed]
[23] Kazmi, F., Nicum, S., Roux, R.L., et al. (2021) A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clin-ical Cancer Research, 27, 3028-3038. [Google Scholar] [CrossRef]